Arcus Biosciences, Inc.
RCUS
$24.90
$0.040.16%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -48.48% | 26.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -48.48% | 26.92% | |||
| Cost of Revenue | 0.83% | -14.18% | |||
| Gross Profit | -19.32% | 23.48% | |||
| SG&A Expenses | 11.54% | -3.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.72% | -12.50% | |||
| Operating Income | -17.54% | 19.72% | |||
| Income Before Tax | -20.75% | 21.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.75% | 21.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.75% | 21.48% | |||
| EBIT | -17.54% | 19.72% | |||
| EBITDA | -18.92% | 20.71% | |||
| EPS Basic | -14.11% | 29.43% | |||
| Normalized Basic EPS | -14.11% | 29.43% | |||
| EPS Diluted | -14.11% | 29.43% | |||
| Normalized Diluted EPS | -14.11% | 29.43% | |||
| Average Basic Shares Outstanding | 5.82% | 11.27% | |||
| Average Diluted Shares Outstanding | 5.82% | 11.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||